Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01199367 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability, and Efficacy Study in Subjects With Advanced or Metastatic Breast Cancer
A Phase 1 study, sponsored by Kyowa Kirin Co..
- Terminated
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
NCT01199367: Clinical Trial Phase 1 study, sponsored by Kyowa Kirin Co..
NCT01199367 is a Phase 1 study that was terminated before completion, run by Kyowa Kirin Co.. The registered enrollment target is 11 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (82% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01199367, a Phase 1 study, was terminated before completion, sponsored by Kyowa Kirin Co..
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
This study will determine the highest dose of KW-2450 in combination with lapatinib and letrozole that can be administered safely to subjects with advanced or metastatic breast cancer and to evaluate its effectiveness. This study was terminated in Phase 1 and never proceeded to the Phase 2 portion of the study.
Interventions
- DRUG KW-2450 in combination with lapatinib and letrozole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2010-12 |
| Est. Completion | 2012-12 |
| Phase | Phase 1 |
Why NCT01199367 stopped before completion
NCT01199367 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 11 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (82% lower).
The record links to 0 conditions, and to 1 intervention - of which KW-2450 in combination with lapatinib and letrozole is the first listed.
NCT01199367 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01199367 about?
NCT01199367 is a clinical study titled "Safety, Tolerability, and Efficacy Study in Subjects With Advanced or Metastatic Breast Cancer". This study will determine the highest dose of KW-2450 in combination with lapatinib and letrozole that can be administered safely to subjects with advanced or metastatic breast cancer and to evaluate its effectiveness. This study was terminated in Phase 1 and never proceeded to the Phase 2 portion ...
What is the current status of trial NCT01199367?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2010-12. Estimated completion is 2012-12.
What interventions are being tested in trial NCT01199367?
The interventions under investigation include: KW-2450 in combination with lapatinib and letrozole (DRUG).
Who is sponsoring clinical trial NCT01199367?
This trial is sponsored by Kyowa Kirin Co., which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01199367's enrollment target sits among peer trials
11 1911th of 2000 higher than 88 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03114462 · 11 participants · Phase 1
Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer
- NCT06039709 · 11 participants · Phase 1
Sonodynamic Therapy in Patients With Recurrent GBM
- NCT06425380 · 11 participants · NA
Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy
- NCT06472661 · 11 participants · Early Phase 1
FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia